StockData
Propanc Biopharma, Inc. logo

Propanc Biopharma, Inc. (PPCB) stock

PPCBNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 2/30
$1.88−0.01 (-0.53%)

Close on Nov 17, 2026Market cap $1.85MP/E –Yield –

Propanc Biopharma operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Propanc Biopharma's operating income for the twelve months ending Sep 30, 2026 was -$22.08M. For fiscal 2026 it was -$18.19M. The highest annual figure on record is -$761.22K in fiscal 2014.

Annual operating income

PeriodPeriod endValueChange
FY2026Jun 30, 2026-$18.19M–
FY2025Jun 30, 2025-$57.28M–
FY2024Jun 30, 2024-$1.54M–
FY2023Jun 30, 2023-$1.78M–
FY2022Jun 30, 2022-$1.99M–
FY2021Jun 30, 2021-$1.81M–
FY2020Jun 30, 2020-$3.49M–
FY2019Jun 30, 2019-$2.61M–
FY2018Jun 30, 2018-$3.96M–
FY2017Jun 30, 2017-$5.74M–
FY2016Jun 30, 2016-$6.90M–
FY2015Jun 30, 2015-$1.71M–
FY2014Jun 30, 2014-$761.22K–
FY2013Jun 30, 2013-$1.36M–
FY2012Jun 30, 2012-$11.59M–
FY2011Jun 30, 2011-$2.24M–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ3 2026Sep 30, 2026-$8.57M–
Q4 FY2026CQ2 2026Jun 30, 2026-$3.46M–
Q3 FY2026CQ1 2026Mar 31, 2026-$6.40M–
Q2 FY2026CQ4 2025Dec 31, 2025-$3.65M–
Q1 FY2026CQ3 2025Sep 30, 2025-$4.67M–
Q4 FY2025CQ2 2025Jun 30, 2025-$3.65M–
Q3 FY2025CQ1 2025Mar 31, 2025-$53.13M–
Q2 FY2025CQ4 2024Dec 31, 2024-$213.38K–
Q1 FY2025CQ3 2024Sep 30, 2024-$290.79K–
Q4 FY2024CQ2 2024Jun 30, 2024-$259.90K–
Q3 FY2024CQ1 2024Mar 31, 2024-$420.87K–
Q2 FY2024CQ4 2023Dec 31, 2023-$438.06K–
Q1 FY2024CQ3 2023Sep 30, 2023-$417.22K–
Q4 FY2023CQ2 2023Jun 30, 2023-$209.60K–
Q3 FY2023CQ1 2023Mar 31, 2023-$386.21K–
Q2 FY2023CQ4 2022Dec 31, 2022-$608.00K–
Q1 FY2023CQ3 2022Sep 30, 2022-$572.83K–
Q4 FY2022CQ2 2022Jun 30, 2022-$599.19K–
Q3 FY2022CQ1 2022Mar 31, 2022-$502.18K–
Q2 FY2022CQ4 2021Dec 31, 2021-$403.47K–
Q1 FY2022CQ3 2021Sep 30, 2021-$486.03K–
Q4 FY2021CQ2 2021Jun 30, 2021-$726.94K–
Q3 FY2021CQ1 2021Mar 31, 2021-$427.95K–
Q2 FY2021CQ4 2020Dec 31, 2020-$274.09K–
Q1 FY2021CQ3 2020Sep 30, 2020-$383.16K–
Q4 FY2020CQ2 2020Jun 30, 2020-$594.07K–
Q3 FY2020CQ1 2020Mar 31, 2020-$607.17K–
Q2 FY2020CQ4 2019Dec 31, 2019-$1.38M–
Q1 FY2020CQ3 2019Sep 30, 2019-$909.42K–
Q4 FY2019CQ2 2019Jun 30, 2019-$836.33K–
Q3 FY2019CQ1 2019Mar 31, 2019-$571.73K–
Q2 FY2019CQ4 2018Dec 31, 2018-$757.82K–
Q1 FY2019CQ3 2018Sep 30, 2018-$448.87K–
Q4 FY2018CQ2 2018Jun 30, 2018-$511.75K–
Q3 FY2018CQ1 2018Mar 31, 2018-$807.14K–
Q2 FY2018CQ4 2017Dec 31, 2017-$1.44M–
Q1 FY2018CQ3 2017Sep 30, 2017-$1.20M–
Q4 FY2017CQ2 2017Jun 30, 2017-$1.11M–
Q3 FY2017CQ1 2017Mar 31, 2017-$1.55M–
Q2 FY2017CQ4 2016Dec 31, 2016-$1.91M–

More Propanc Biopharma figures

See a number that looks wrong?